Primary Endpoint Data from Phase I Part B

MinervaX announces that it today data have been received from the primary 3-month time point clinical endpoint of the Phase I Part B. The data supports dose-selection made based on Part A. The data further supports the vaccine is highly immunogenic already 14 days after the first dose, and that the antibodies are functionally active in killing Group B Streptococcus and preventing host-invasion.